Lower arrythmogenic risk of low dose albuterol plus ipratropium

Simple item page
dc.contributor.authorYuksel H.
dc.contributor.authorCoskun S.
dc.contributor.authorPolat M.
dc.contributor.authorOnag A.
dc.date.accessioned2024-07-22T08:25:25Z
dc.date.available2024-07-22T08:25:25Z
dc.date.issued2001
dc.description.abstractObjective: Wheezy infants are in need of urgent bronchodilatation owing to their intermittent bronchoconstriction. β2 agonists are frequently used in emergencies and have previously shown to increase the QT dispersion (QTd), which may be associate with high risk of cardiac arrhythmia, in asthmatics. However, effect of low dose β2 agonist therapy in combination with the anticholinergic agents on QTd in wheezy infants is not known. This study aimed to assess the effect of standard dose of nebulized albuterol (NAB) and low doses of NAB combined with ipratropium-bromide (NIB) on QTd in wheezy infants. Methods: Twenty-nine children, under 2 years old, with the diagnosis of wheezy infant with acute exacerbation were enrolled in the study. Thirteen were treated by standard dose of NA therapy (0.15 mg/kg) and low doses of NAB (0.075 mg/kg) plus NIB (250 μg/dose) therapy was given to the remaining subjects. Respiratory distress score, 02 saturation and side effects were studied and QTd were measured from the standard electrocardiograms at baseline and after treatment. Significant improvement was achieved in clinical score and oxygenation of both groups. Result: The evaluation of the corrected QTd (QTcd) showed that there was no significant difference between pretreatment values of both groups (p>0.05). However, while there was no statistically significant difference in the pre and post-treatment values of QTcd of infants treated with combination therapy, QTcd was found to be significantly increased in NAB group after treatment (p<0.05). Conclusion: Our results suggest that, while clinical improvement is same, the increase of the QT dispersion is more prominent with the use of standard dose of NAB compared to low dose NAB plus NIB therapy. So, low dose of β2 agonist in combination with anticholinergic agents may much safer than the use of standard dose of β2 agonists alone in regard to preventing the possibility of arrythmogenic effects in wheezy infants with acute exacerbation.
dc.identifier.DOI-ID10.1007/BF02722593
dc.identifier.issn00195456
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20412
dc.language.isoEnglish
dc.publisherThe Indian Journal of Pediatrics
dc.subjectbeta adrenergic receptor stimulating agent
dc.subjectcholinergic receptor blocking agent
dc.subjectipratropium bromide
dc.subjectsalbutamol
dc.subjectventolin nebule
dc.subjectarrhythmogenesis
dc.subjectarticle
dc.subjectasthma
dc.subjectbronchodilatation
dc.subjectbronchospasm
dc.subjectcardiovascular risk
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdisease association
dc.subjectdisease exacerbation
dc.subjectdose response
dc.subjectdrug safety
dc.subjectfemale
dc.subjectheart arrhythmia
dc.subjecthigh risk population
dc.subjecthuman
dc.subjectmale
dc.subjectoxygen saturation
dc.subjectoxygenation
dc.subjectpreschool child
dc.subjectQT interval
dc.subjectrandomized controlled trial
dc.subjectrespiratory distress
dc.subjectrisk factor
dc.subjecttreatment planning
dc.subjectwheezing
dc.titleLower arrythmogenic risk of low dose albuterol plus ipratropium
dc.typeArticle

Files

Collections

Scopus Koleksiyonu